Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.83 |
| ▸ | CXCR1 | P25024 | 10/20 | 0.79 |
| ▸ | CCR7 | P32248 | 1/20 | 0.79 |
| ▸ | CCR6 | P51684 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262972 | 0.91 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12573315 | 0.91 | CXCR2 (0.85) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL12262719 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL184744 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL1446663 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL14511488 | 0.88 | CXCR2 (0.79) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024683 | 0.87 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024684 | 0.87 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12310920 | 0.85 | CXCR2 (0.75) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL20452298 | 0.84 | CXCR2 (0.74) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723131-B1 | CRYSTALLINE POLYMORPHS OF A CXC-CHEMOKINE RECEPTOR LIGAND | SCHERING CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009073683-A2 | METHODS OF TREATING COPD | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |